These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35194014)

  • 1. Growth differentiation factor 15 (GDF15) is associated with non-alcoholic fatty liver disease (NAFLD) in youth with overweight or obesity.
    Galuppo B; Agazzi C; Pierpont B; Chick J; Li Z; Caprio S; Santoro N
    Nutr Diabetes; 2022 Feb; 12(1):9. PubMed ID: 35194014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease.
    Pacifico L; Di Martino M; Anania C; Andreoli GM; Bezzi M; Catalano C; Chiesa C
    World J Gastroenterol; 2015 Apr; 21(15):4688-95. PubMed ID: 25914480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
    Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
    Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage.
    Giannini C; Feldstein AE; Santoro N; Kim G; Kursawe R; Pierpont B; Caprio S
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2993-3000. PubMed ID: 23626003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity.
    Rauzier C; Chartrand DJ; Alméras N; Lemieux I; Larose E; Mathieu P; Pibarot P; Lamarche B; Rhéaume C; Poirier P; Després JP; Picard F
    Front Endocrinol (Lausanne); 2023; 14():1222101. PubMed ID: 37854178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight Loss Induced by Bariatric Surgery Restricts Hepatic
    Adolph TE; Grabherr F; Mayr L; Grander C; Enrich B; Moschen AR; Tilg H
    J Obes; 2018; 2018():7108075. PubMed ID: 30533221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice.
    Li D; Zhang H; Zhong Y
    Biochem Biophys Res Commun; 2018 Apr; 498(3):388-394. PubMed ID: 28847729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease.
    Lee S; Rivera-Vega M; Alsayed HM; Boesch C; Libman I
    Pediatr Diabetes; 2015 May; 16(3):211-8. PubMed ID: 24754380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.
    Wang Y; Chen C; Chen J; Sang T; Peng H; Lin X; Zhao Q; Chen S; Eling T; Wang X
    Redox Biol; 2022 Jun; 52():102322. PubMed ID: 35504134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors.
    Lee S; Kim KW; Lee J; Park T; Koo K; Song GW; Lee SG
    Transplant Proc; 2022 Apr; 54(3):702-705. PubMed ID: 35256204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity.
    Chen J; Yue J; Fu J; He S; Liu Q; Yang M; Zhang W; Xu H; Lu Q; Ma J
    Endocr J; 2023 Oct; 70(10):977-985. PubMed ID: 37599066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between regional fat mass and risk of nonalcoholic fatty liver disease in overweight/obese adults].
    Zeng Y; Yuan S; Xie M; Xiao T; Huang Z; Zhou J; He Q; Yang Y; Ma J
    Wei Sheng Yan Jiu; 2022 Sep; 51(5):753-760. PubMed ID: 36222034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease.
    Goffredo M; Santoro N; Tricò D; Giannini C; D'Adamo E; Zhao H; Peng G; Yu X; Lam TT; Pierpont B; Caprio S; Herzog RI
    Nutrients; 2017 Jun; 9(7):. PubMed ID: 28640216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity.
    Leone A; Bertoli S; Bedogni G; Vignati L; Pellizzari M; Battezzati A
    Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
    Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
    Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study.
    Parker HM; O'Connor HT; Keating SE; Cohn JS; Garg ML; Caterson ID; George J; Johnson NA
    Br J Nutr; 2015 Sep; 114(5):780-7. PubMed ID: 26202539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
    Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
    Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.